Amedisys (NASDAQ:AMED) Reaches New 52-Week Low - Should You Sell?

Amedisys, Inc. (NASDAQ:AMED - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $83.73 and last traded at $83.78, with a volume of 910801 shares traded. The stock had previously closed at $84.97.

Amedisys Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The company has a market cap of $2.74 billion, a price-to-earnings ratio of 33.25, a price-to-earnings-growth ratio of 1.84 and a beta of 0.73. The stock has a 50-day moving average price of $91.75 and a 200 day moving average price of $94.68.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.19). The company had revenue of $587.67 million for the quarter, compared to analyst estimates of $586.75 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business's quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business posted $0.98 earnings per share. As a group, analysts anticipate that Amedisys, Inc. will post 4.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Amedisys

A number of large investors have recently added to or reduced their stakes in the company. Polar Asset Management Partners Inc. acquired a new stake in shares of Amedisys in the third quarter valued at approximately $28,953,000. SG Americas Securities LLC grew its position in Amedisys by 413.4% in the third quarter. SG Americas Securities LLC now owns 196,713 shares of the health services provider's stock valued at $18,985,000 after purchasing an additional 158,398 shares in the last quarter. Verition Fund Management LLC increased its stake in Amedisys by 608.1% in the 3rd quarter. Verition Fund Management LLC now owns 114,774 shares of the health services provider's stock valued at $11,077,000 after buying an additional 98,565 shares during the last quarter. Westchester Capital Management LLC lifted its position in Amedisys by 9.5% during the 3rd quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider's stock worth $107,976,000 after buying an additional 97,476 shares in the last quarter. Finally, Highbridge Capital Management LLC boosted its stake in shares of Amedisys by 34.7% during the 2nd quarter. Highbridge Capital Management LLC now owns 323,200 shares of the health services provider's stock worth $29,670,000 after buying an additional 83,200 shares during the last quarter. Institutional investors own 94.36% of the company's stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.